Home   About this service   Get the news  
+32 2 743 34 03

 
UCB [BE0003739530 / UCB]

UCB Media Room: Acquisitions and Disposals of own shares

INFORMATION REGLEMENTEE


[20/04/2021 | 20:04]
https://mb.cision.com/Public/18595/logo/86a99b25f755738d_org.jpg

** Acquisitions of own shares and Disposals of own shares
------------------------------------------------------------

Brussels (Belgium), 20 April 2021 =E2=80=93 20:00 (CEST) =E2=80=93 regulate=
d information

Acquisitions of own shares

In accordance with article 8:4 of the Royal Decree of 29 April 2019 executi=
ng the Belgian Code on Companies and Associations, UCB SA/NV (=E2=80=9CUCB=
=E2=80=9D or the =E2=80=9CCompany) (Euronext Brussels: UCB) hereby disclose=
s certain information in relation to its Share Repurchase Program 2021.=C2=
=A0

Under this program, UCB has requested a financial intermediary to repurchas=
e up to 750 000 UCB shares on its behalf under the terms of an initial disc=
retionary mandate agreement with validity until 25 June 2021, effective as =
from 8 March 2021, to cover current and future obligations under UCB's Long=
Term Incentive Plans for its personnel.

In the framework of this Share Repurchase Program 2021, UCB repurchased 139=
026 UCB shares on Euronext Brussels in the period from 9 April 2021 up to =
and including 19 April 2021, as follows:=C2=A0

https://mb.cision.com/Public/18595/3329520/bf8e643c2cb61c8e_800x800ar.png

Disposals of own shares

For consistency reasons, UCB confirms that during the same period, it has n=
ot disposed of any UCB shares within the framework of the Long Term Incenti=
ve Program of the UCB Group.

This press release is available on UCB SA/NV=E2=80=99s website via the foll=
owing link (https://www.ucb.com/stories-media/Press-Releases) .

Investor Relations
Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company =
focused on the discovery and development of innovative medicines and soluti=
ons to transform the lives of people living with severe diseases of the imm=
une system or of the central nervous system. With approximately 8 400 peopl=
e in nearly 40 countries, the company generated revenue of =E2=82=AC 5.3 bi=
llion in 2020. UCB is listed on Euronext Brussels (symbol: UCB). Follow us =
on Twitter: @UCB_news
=C2=A0
GenericFile
210420 - UCB Acquisitions and disposals of own shares ENG (https://mb.cisio=
n.com/Public/18595/3329520/914c0542c8ef230f.pdf) GenericFile
210420 - Rachat et ali=C3=A9nation d actions propres FR (https://mb.cision.=
com/Public/18595/3329520/b45c430f2d0b721c.pdf) GenericFile
210420 - Verwerving en vervreemding van eigen aandelen NED (https://mb.cisi=
on.com/Public/18595/3329520/a7120d2ac7702b9a.pdf) Image
Chart 1 April 20 2021 (https://mb.cision.com/Public/18595/3329520/bf8e643c2=
cb61c8e_org.png)=0D
=0D
______________________=0D
If you would rather not receive future communications from UCB SA, please g=
o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x67106x1x6868579x24000=
x6&Email=3Dregnews%40symexglobal.com.=0D
UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=